Intravitreous ranibizumab (lucentis) for radiation maculopathy.
Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY 10065, USA. pfinger@eyecancer.com
Paul T
PT
Finger
Kimberly J
KJ
Chin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001918:Brachytherapy / Q000009:adverse effects*; D002830:Choroid Neoplasms / Q000532:radiotherapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000528:radiation effects*; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008545:Melanoma / Q000532:radiotherapy; D008875:Middle Aged; D010165:Palladium / Q000009:adverse effects; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology; D011868:Radioisotopes / Q000009:adverse effects; D000069579:Ranibizumab; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology; D012166:Retinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D015861:Retinal Neovascularization / Q000188:drug therapy / Q000209:etiology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011868:Radioisotopes; D010165:Palladium; D000069579:Ranibizumab